Wexner Medical Center, First Trial Site Opened for Experimental Gene Therapy Testing in Frontotemporal Degeneration Patients

AviadoBio reported last month that its ASPIRE-FTD phase 1/2 clinical trial opened its first trial site in the United States, at Ohio State University’s Wexner Medical Center. The company is evaluating the experimental gene therapy AVB-101 as an intervention for FTD caused by a variant of the GRN gene. Also, TrialSite reports the Ohio Wexner Medical Center is rated among the best in the country for research.

The Gene Therapy